Consortium Highlights & Events
Consortium Highlights & Events
Consortium Highlights & Events
September, 2024
PETAL consortium’s second site Dana Farber Cancer Institute (DFCI) is successfully activated for enrollment
PETAL consortium’s second site Dana Farber Cancer Institute (DFCI) is successfully activated for enrollment
August, 2024
Daiichi Sankyo Inc. and Kyowa Kirin join as the key sponsors to advance the future research at PETAL consortium
Daiichi Sankyo Inc. and Kyowa Kirin join as the key sponsors to advance the future research at PETAL consortium
July, 2024
Acrotech Biopharma joins PETAL, supporting the development of the consortium and personalized treatments for rare lymphomas.
Acrotech Biopharma joins PETAL, supporting the development of the consortium and personalized treatments for rare lymphomas.
June, 2024
May, 2024
Mark Sorial receives an educational grant from SecuraBio to develop novel machine learning models to estimate outcomes for patients with peripheral T-cell lymphoma.
Mark Sorial receives an educational grant from SecuraBio to develop novel machine learning models to estimate outcomes for patients with peripheral T-cell lymphoma.
February, 2024
PETAL Consortium’s first site Massachusetts General Hospital (MGH) is successfully activated for patient enrollment
PETAL Consortium’s first site Massachusetts General Hospital (MGH) is successfully activated for patient enrollment
December, 2023
The first PETAL Investigators meeting was held at ASH 2023 conference discussing the scope of PETAL and future of T-cell Lymphoma research.
The first PETAL Investigators meeting was held at ASH 2023 conference discussing the scope of PETAL and future of T-cell Lymphoma research.
@2024 PETAL Consortium • All rights reserved
@2024 PETAL Consortium • All rights reserved